Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: Analysis of 1406 patients

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 353-360

  Rudick, R A ^a   Kappos, L ^b   Kinkel, R ^c   Clanet, M ^d   Phillips, J T ^e   Herndon, R M ^f   Sandrock, A W ^g   Munschauer, F E ^g,h  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d CHU PURPAN   (France)

^e Multiple Sclerosis Center at Texas Neurology   (United States)

^f UNIVERSITY OF MISSISSIPPI   (United States)

^g BIOGEN   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adverse events; annualized relapse rate; clinically isolated syndrome; disability progression; gadolinium enhanced lesions; IM IFN 1a; multiple sclerosis; neutralizing antibodies; relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; PLACEBO;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; GENDER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RELAPSE; URINARY TRACT INFECTION;

EID: 79953195171     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510384605     Document Type: Article

References (30)

1. Food and Drug Administration. Summary basis for approval: interferon beta-1a. http://www.fda.gov/cder/biologics/sba/ifnbbio051796s.pdf. (published 17 February 2005 ; accessed 7 September 2006 ).
2. Tomassini V., Paolillo A., Russo P., Giugni E., Prosperini L., Gasperini C., et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006 ; 253: 287-293.
3. Monzani F., Caraccio N., Meucci G., Lombardo F., Moscato G., Casolaro A., et al. Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999 ; 141: 325-331. 4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39: 285-294. (Pubitemid 29529483)
4. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000 ; 343: 898-904.
5. Clanet M., Radue EW, Kappos L., Hartung HP, Hohlfeld R., Sandberg-Wollheim M., et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002 ; 59: 1507-1517. (Pubitemid 35387054)
6. Herndon RM, Rudick RA, Munschauer III FE, Mass MK, Salazar AM, Coats ME, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005 ; 11: 409-419. (Pubitemid 40984235)
7. Phillips JT, Rice G., Frohman E., Vande Gaer L., Scott T., Haas J., et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004 ; 26: 511-521. (Pubitemid 38586452)
8. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J., Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 ; 50: 701-708.
9. IFNβ Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
10. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J., Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 ; 45: 1268-1276.
11. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
12. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 ; 352: 1491-1497.
13. Comi G., Filippi M., Wolinsky JS and the European/ Canadian Glatiramer Acetate Study Group. European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001 ; 49: 290-297. (Pubitemid 32202781)
14. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernández O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 ; 357: 1576-1582. (Pubitemid 32488815)
15. Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 ; 359: 1453-1460. (Pubitemid 34457761)
16. Panitch H., Goodin DS, Francis G., Chang P., Coyle PK, O'Connor P., et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial. Neurology 2002 ; 59: 1496-1506. (Pubitemid 35387053)
17. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study. Neurology 2004 ; 63: 1788-1795.
18. Freedman MS, Francis GS, Sanders EA, Rice GP, O'Connor P., Comi G., et al. Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005 ; 11: 41-45. (Pubitemid 40259973)
19. Filippi M., Wolinsky JS and Comi G. and the CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006 ; 5: 213-220. (Pubitemid 43238344)
20. Kappos L., Polman CH, Freedman MS, Edan G., Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67: 1242-1249. (Pubitemid 44563835)
21. Kappos L., Freedman MS, Polman CH, Edan G., Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 ; 370: 389-397. (Pubitemid 47189673)
22. Patten SB, Metz LM and Reimer MA Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000 ; 6: 115-120. (Pubitemid 30218905)
23. Khan F., McPhail T., Brand C., Turner-Stokes L. and Kilpatrick T. Multiple sclerosis: disability profile and quality of life in an Australian community cohort. Int J Rehabil Res 2006 ; 29: 87-96. (Pubitemid 44309727)
24. Zephir H., De Seze J., Stojkovic T., Delisse B., Ferriby D., Cabaret M., et al. Multiple sclerosis and depression: influence of interferon β therapy. Mult Scler 2003 ; 9: 284-288. (Pubitemid 36681895)
25. Patten SB, Fridhandler S., Beck CA and Metz LM Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003 ; 9: 616-620. (Pubitemid 37479412)
26. Galeazzi GM, Ferrari S., Giaroli G., Mackinnon A., Merelli E., Motti L., et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005 ; 26: 255-262. (Pubitemid 41447824)
27. Patten SB, Francis G., Metz LM, Lopez-Bresnahan M., Chang P. and Curtin F. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005 ; 11: 175-181. (Pubitemid 40403256)
28. Patten SB, Beck CA, Williams JVA, Barbui C. and Metz LM Major depression in multiple sclerosis. A population-based perspective. Neurology 2003 ; 61: 1524-1527. (Pubitemid 37505573)
29. Patten SB, Svenson LW and Metz LM Descriptive epidemiology of affective disorders in multiple sclerosis. CNS Spectr 2005 ; 10: 365-371. (Pubitemid 41001889)
30. Stewart WF, Lipton RB, Celentano DD and Reed ML Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992 ; 267: 64-69.